Cristobal Cruz-Colon, MD
Ophthalmology · Ponce, PRNPI 1548455868
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,913 of the $43,954 with a category attached, or 79.4%. AbbVie accounts for 92.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $27,072 and has fallen 99.2% since, to $208 in 2025. Among ophthalmology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $435.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$41K
- Carl Zeiss Meditec USA, Inc.$2K
- Johnson & Johnson Surgical Vision, Inc.$961
- Mallinckrodt Hospital Products Inc.$120
- Sanofi$108
- Alcon Puerto Rico Inc$46
- plus $140 from 6 others
What the payments were for
- Speaking & faculty fees$34,91379%
- Travel & lodging$7,13316%
- Food & beverage$1,7844%
- Education$800%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $40,616 |
| Carl Zeiss Meditec USA, Inc. | 4 | $1,962 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $961 |
| Mallinckrodt Hospital Products Inc. | 3 | $120 |
| Sanofi | 1 | $108 |
| Alcon Puerto Rico Inc | 2 | $46 |
| NEW World Medical,inc. | 2 | $37 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Bausch & Lomb Americas Inc. | 1 | $22 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$15,692
- DURYSTA$12,120
- LUMIGAN$8,197
- XEN$3,073
- ARTEVO 800$1,809
- CIRRUS HD-OCT$1,809
- IOLMaster 700$1,809
- VERACITY SURGICAL$1,809
- VisuMax$1,809
- Tecnis 1-piece IOL$846
- Tecnis Multifocal Family of 1-piece IOLS$846
- Tecnis Symfony IOL$846
- COMBIGAN$400
How this compares
$43,954 in reported general payments places this provider in the 95th percentile of 214 ophthalmology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 756 | $490,765 |
| LumiganBimatoprost | 912 | $255,798 |
| Fluorometholone | 2,041 | $143,056 |
| CombiganBrimonidine Tartrate/Timolol | 468 | $102,816 |
| XiidraLifitegrast | 97 | $68,812 |
| Cyclosporine | 315 | $66,373 |
| Latanoprost | 4,171 | $59,104 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 362 | $56,659 |
| Prednisolone Acetate | 977 | $37,032 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 934 | $29,791 |
| AzoptBrinzolamide | 69 | $26,183 |
| Ketorolac Tromethamine | 548 | $20,352 |
| Ofloxacin | 841 | $19,328 |
| Timolol Maleate | 1,065 | $15,078 |
| Brimonidine Tartrate | 1,016 | $13,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $40,616 | $860,2722,178 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $22 | $74,258118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 214 ophthalmology providers in Puerto Rico.
Other ophthalmology in Ponce
- Luis Serrano TorresPonce$1K
- Maria Berrocal FernandezSan Juan$547K
- Jose MontesSan Juan$396K
- Armando OliverRio Piedras$251K
- Andres Emanuelli AnzalottaCorozal$50K
- Juan Nevarez MarreroSan Juan$19K
- Natalio Izquierdo EncarnacionSan Juan$16K
- Ian PiovanettiSan Juan$11K
- Antolin Alvarez PontSanturce$10K
- Jaime Bravo CastroSan Juan$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.